On Monday, Shares of Nokia Corp (ADR) (NYSE:NOK), added 0.73% and closed at $5.53 in the last trading session. The last trading range of the stock ranges between $5.49 and $5.56. The company’s Market capitalization is $31.81 Billion with the total Outstanding Shares of 5.77 Billion. During the 52-week trading session the minimum price at which share price traded, registered at $5.01 and reached to max level of $7.63. Nokia is expanding its carrier SDN offering by adding assurance capabilities to its Network Services Platform (NSP ). Combined with the NSP’s automation and network control features, assurance equips operators with the tools to establish and maintain healthy SDN networks and services, even as the dynamic consumption patterns of cloud applications makes demand and traffic patterns less predictable. Assurance provides the missing link operators need to start large-scale commercial SDN deployment, spurred by the growth of cloud, video and Internet of Things (IoT).
Operators recently need to ensure the on-demand network services they bring to market are delivered using automated provisioning that makes the best use of available assets through real-time network control. But, as SDN projects move from limited live trials to broad deployment and commercialization, providers are discovering they need assurance in addition to automation with inline optimization.
Nokia SDN automation and control capabilities allow operators to make assurance processes far more efficient and impactful than ever before. With automated (or dynamic) assurance, KPIs and analytics can be used to dynamically trigger changes at the SDN control layer without the need for manual intervention.
Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA), dropped -0.04% and closed at $45.04 in the last trading session. The last trading range of the stock ranges between $44.89 and $45.85. The company’s Market capitalization is $46.06 Billion with the total Outstanding Shares of 1.01 Billion. During the 52-week trading session the minimum price at which share price traded, registered at $44.60 and reached to max level of $66.55. Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. The companys Generic Medicines segment offers generic medicines, such as sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, counting tablets, capsules, injectables, inhalants, liquids, ointments, and creams. This segment also develops, manufactures, and sells active pharmaceutical ingredients. The companys Specialty Medicines segment provides branded specialty medicines for use in central nervous system and respiratory indications, in addition to the womens health, oncology, and other specialty businesses. Its products in the central nervous system area comprise Copaxone for multiple sclerosis; Azilect for the treatment of Parkinsons disease; Nuvigil for the treatment of excessive sleepiness associated with narcolepsy and certain other disorders; Fentora/Effentora for the treatment of breakthrough pain in opioid-tolerant adult patients with cancer; and Zecuity, a prescription transdermal system for the acute treatment of migraine with or without aura in adults. This segments products in the respiratory market include ProAir, ProAir Respiclick, QVAR, and Duoresp Spiromax for the treatment of asthma and chronic obstructive pulmonary disease, in addition to Treanda, Granix, Trisenox, Synribo, Lonquex, Myocet, Eporatio, Tevagrastim/Ratiograstim, and Trisenox products in the oncology market.